Identification

Name
Dabrafenib
Accession Number
DB08912
Type
Small Molecule
Groups
Approved
Description

Dabrafenib mesylate is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. FDA approved on May 29, 2013.

Structure
Thumb
Synonyms
  • Dabrafenib
External IDs
GSK-2118436 / GSK-2118436A / GSK2118436 / GSK2118436A
Product Ingredients
IngredientUNIICASInChI Key
Dabrafenib MesylateB6DC89I63E1195768-06-9YKGMKSIHIVVYKY-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TafinlarCapsule50 mgOralNovartis2013-08-28Not applicableCanada
TafinlarCapsule75 mg/1OralGlaxosmithkline Inc2013-06-102018-05-31Us
TafinlarCapsule75 mgOralNovartis2013-08-28Not applicableCanada
TafinlarCapsule75 mg/1OralNovartis2016-04-01Not applicableUs
TafinlarCapsule50 mg/1OralGlaxosmithkline Inc2013-06-102018-08-31Us
TafinlarCapsule50 mg/1OralNovartis2016-04-12Not applicableUs
Categories
UNII
QGP4HA4G1B
CAS number
Not Available
Weight
Average: 519.562
Monoisotopic: 519.101050904
Chemical Formula
C23H20F3N5O2S2
InChI Key
BFSMGDJOXZAERB-UHFFFAOYSA-N
InChI
InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)
IUPAC Name
N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene-1-sulfonamide
SMILES
CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1

Pharmacology

Indication

Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

Structured Indications
Pharmacodynamics

Dabrafenib caused an inhibition of phosphorylated ERK. This indicates a decrease in cell proliferation. Furthermore, within 24 hours of administration, downstream mediators of the MAPK pathway were inhibited.

Mechanism of action

Dabrafenib is an inhibitor of some mutated forms of BRAF kinases with in vitro IC50 values of 0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes, respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC50 values of 3.2 and 5.0 nM, respectively, and other kinases such as SIK1, NEK11, and LIMK1 at higher concentrations. Some mutations in the BRAF gene, including those that result in BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth.

TargetActionsOrganism
ASerine/threonine-protein kinase B-raf
inhibitor
Human
ARAF proto-oncogene serine/threonine-protein kinase
inhibitor
Human
USerine/threonine-protein kinase SIK1
inhibitor
Human
USerine/threonine-protein kinase Nek11
inhibitor
Human
ULIM domain kinase 1
inhibitor
Human
Absorption

After oral administration, median time to achieve peak plasma concentration (Tmax) is 2 hours. Mean absolute bioavailability of oral dabrafenib is 95%.

Volume of distribution

Apparent volume of distribution (Vd/F) = 70.3 L. Distribution to the brain is restricted because dabrafenib is a substrate and undergoes efflux by P-glycoprotein and breast cancer resistance protein.

Protein binding

99.7% bound to human plasma protein.

Metabolism

Dabrafenib is hepatically metabolized. The biotransformation process is primarily mediated by CYP2C8 and CYP3A4 to form hydroxy-debrafenib. This metabolite is further oxidized via CYP3A4 to form carboxy-dabrafenib and subsequently excreted in bile and urine. Carboxy-dabrafenib can also undergo decarboxylation to form desmethyl-dabrafenib, which may be reabsorbed from the gut. Desmethyl-dabrafenib is further metabolized by CYP3A4 to oxidative metabolites.

Route of elimination

71% of the dose is excreted in feces. 23% of the dose is excreted in the urine as metabolites only.

Half life

Dabrafenib = 8 hours; Hydroxy-dabrafenib = 10 hours; Carboxy-dabrafenib = 21-22 hours; Desmethyl-dabrafenib = 21- 22 hours.

Clearance

The apparent clearance of dabrafenib is 17.0 L/h after single dosing and 34.4 L/h after 2 weeks of twice daily dosing.

Toxicity

Most common adverse reactions (≥20%) for dabrafenib are hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Glucose-6-phosphate 1-dehydrogenaseVilleurbanneNot Available1000_1002delACCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTorunNot Available1006A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSunderlandNot Available105_107delCATADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIwatsukiNot Available1081G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSerresNot Available1082C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTondelaNot Available1084_1101delCTGAACGAGCGCAAGGCCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLoma LindaNot Available1089C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAachenNot Available1089C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTenriNot Available1096A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontpellierNot Available1132G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCalvo MackennaNot Available1138A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRileyNot Available1139T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOlomoucNot Available1141T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTomahNot Available1153T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLynwoodNot Available1154G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMadridNot Available1155C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIowa, Walter Reed, SpringfieldNot Available1156A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBeverly Hills, Genova, Iwate, Niigata, YamaguchiNot Available1160G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHartfordNot Available1162A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePrahaNot Available1166A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKrakowNot Available1175T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWisconsinNot Available1177C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNashville, Anaheim, PorticiNot Available1178G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAlhambraNot Available1180G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBariNot Available1187C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePuerto LimonNot Available1192G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCovao do LoboNot Available1205C>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseClinicNot Available1215G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUtrechtNot Available1225C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSuwalkiNot Available1226C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRiversideNot Available1228G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseJapan, ShinagawaNot Available1229G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKawasakiNot Available1229G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMunichNot Available1231A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGeorgiaNot Available1284C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSumareNot Available1292T->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTelti/KobeNot Available1318C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiago de Cuba, MoriokaNot Available1339G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarimaNot Available1358T->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFiguera da FozNot Available1366G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmiensNot Available1367A>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkok NoiNot Available1376G->T, 1502T->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFukayaNot Available1462G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCampinasNot Available1463G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBuenos AiresNot Available1465C>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseArakawaNot Available1466C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBrightonNot Available1488_1490delGAAADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKozukataNot Available159G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmsterdamNot Available180_182delTCTADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNo nameNot Available202G->A, 376A->G, 1264C>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSwanseaNot Available224T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUrayasuNot Available281_283delAGAADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVancouverNot Available317C->G544C->T592C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMt SinaiNot Available376A->G, 1159C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePlymouthNot Available488G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVolendamNot Available514C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseShinshuNot Available527A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChikugoNot Available535A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTsukuiNot Available561_563delCTCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePedoplis-CkaroNot Available573C>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiagoNot Available593G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMinnesota, Marion, Gastonia, LeJeuneNot Available637G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCincinnatiNot Available637G->T, 1037A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarilaouNot Available648T->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNorth DallasNot Available683_685delACAADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahikawaNot Available695G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseDurhamNot Available713A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseStonybrookNot Available724_729delGGCACTADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWayneNot Available769C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAveiroNot Available806G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCleveland CorumNot Available820G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLilleNot Available821A>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkokNot Available825G>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSugaoNot Available826C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLa JollaNot Available832T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWexhamNot Available833C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePiotrkowNot Available851T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWest VirginiaNot Available910G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOmiyaNot Available921G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaraNot Available953_976delCCACCAAAGGGTACCTGGAC GACCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseManhattanNot Available962G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRehevotNot Available964T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHoniaraNot Available99A->G / 1360C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTokyo, FukushimaNot Available1246G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChathamNot Available1003G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFushanNot Available1004C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePartenopeNot Available1052G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIerapetraNot Available1057C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnadiaNot Available1193A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAbenoNot Available1220A->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSurabayaNot Available1291G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePawneeNot Available1316G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseS. AntiocoNot Available1342A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCassanoNot Available1347G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHermoupolisNot Available1347G->C / 1360C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUnion,Maewo, Chinese-2, KaloNot Available1360C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAndalusNot Available1361G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCosenzaNot Available1376G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCanton, Taiwan- Hakka, Gifu-like, Agrigento-likeNot Available1376G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFloresNot Available1387C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKaiping, Anant, Dhon, Sapporo-like, WoseraNot Available1388G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamogawaNot Available169C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCostanzoNot Available179T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmazoniaNot Available185C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSongklanagarindNot Available196T->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHechiNot Available202G->A / 871G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNamouruNot Available208T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBao LocNot Available352T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCrispimNot Available375G->T, 379G->T383T->C384C>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAcrokorinthosNot Available376A->G / 463C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSanta MariaNot Available376A->G / 542A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnanindeuaNot Available376A->G / 871G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVanua LavaNot Available383T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseValladolidNot Available406C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBelemNot Available409C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLiuzhouNot Available442G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseShenzenNot Available473G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTaipei “Chinese- 3”Not Available493A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseToledoNot Available496C>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaoneNot Available497G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNankangNot Available517T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMiaoliNot Available519C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMediterranean, Dallas, Panama‚ Sassari, Cagliari, BirminghamNot Available563C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCoimbra ShundeNot Available592C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNilgiriNot Available593G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRadlowoNot Available679C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRoubaixNot Available811G>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHaikouNot Available835A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-1Not Available835A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMizushimaNot Available848A>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOsakaNot Available853C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseViangchan, JammuNot Available871G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeoulNot Available916G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLudhianaNot Available929G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFarroupilhaNot Available977C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-5Not Available1024C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRignanoNot Available130G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOrissaNot Available131C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseG6PDNiceNot Available1380G>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamiube, KeelungNot Available1387C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNeapolisNot Available1400C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAuresNot Available143T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSplitNot Available1442C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKambosNot Available148C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePalestrinaNot Available170G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMetapontoNot Available172G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMusashinoNot Available185C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahiNot Available202G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (202), Ferrara INot Available202G->A / 376A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMurcia OristanoNot Available209A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUbe KonanNot Available241C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagosantoNot Available242G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGuangzhouNot Available274C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHammersmithNot Available323T->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSinnaiNot Available34G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (680)Not Available376A->G / 680G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (968), Betica,Selma, GuantanamoNot Available376A->G / 968T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSalerno PyrgosNot Available383T>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseQuing YanNot Available392G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagesNot Available40G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIleshaNot Available466G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMahidolNot Available487G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMalagaNot Available542A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSibariNot Available634A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMexico CityNot Available680G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNanningNot Available703C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeattle, Lodi, Modena, Ferrara II, Athens-likeNot Available844G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBajo MaumereNot Available844G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontalbanoNot Available854G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKalyan-Kerala, Jamnaga, RohiniNot Available949G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGaoheNot Available95A->GADR InferredIncreased risk of hemolytic anemia.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Dabrafenib.Investigational
AbemaciclibThe serum concentration of Abemaciclib can be decreased when it is combined with Dabrafenib.Approved
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Dabrafenib.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Dabrafenib.Approved, Investigational
AceclofenacThe serum concentration of Aceclofenac can be decreased when it is combined with Dabrafenib.Approved, Investigational
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Dabrafenib.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Dabrafenib.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Dabrafenib.Investigational, Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Dabrafenib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Dabrafenib.Experimental
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Dabrafenib.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Dabrafenib.Experimental, Investigational
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Dabrafenib.Approved
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Dabrafenib.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Dabrafenib.Approved, Investigational
AlgeldrateThe serum concentration of Dabrafenib can be decreased when it is combined with Algeldrate.Approved, Experimental
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Dabrafenib.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Dabrafenib.Investigational
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Dabrafenib.Approved
AlmagateThe serum concentration of Dabrafenib can be decreased when it is combined with Almagate.Experimental
AlmasilateThe serum concentration of Dabrafenib can be decreased when it is combined with Almasilate.Approved, Experimental
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Dabrafenib.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Dabrafenib.Approved
AloglutamolThe serum concentration of Dabrafenib can be decreased when it is combined with Aloglutamol.Experimental
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Dabrafenib.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Dabrafenib.Approved, Illicit, Investigational
AluminiumThe serum concentration of Dabrafenib can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Dabrafenib can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Dabrafenib can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Dabrafenib can be decreased when it is combined with Aluminum hydroxide.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Dabrafenib.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Dabrafenib.Approved, Investigational
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Dabrafenib.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Dabrafenib.Approved
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Dabrafenib.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Dabrafenib.Approved
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Dabrafenib.Approved
AmodiaquineThe serum concentration of Amodiaquine can be decreased when it is combined with Dabrafenib.Approved, Investigational
AmoxicillinThe serum concentration of Amoxicillin can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Dabrafenib.Approved
AnagrelideDabrafenib may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Dabrafenib.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Dabrafenib.Approved
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Dabrafenib.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Dabrafenib.Approved, Investigational
Arachidonic AcidThe serum concentration of Arachidonic Acid can be decreased when it is combined with Dabrafenib.Experimental
ArformoterolThe serum concentration of Arformoterol can be decreased when it is combined with Dabrafenib.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Dabrafenib.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Dabrafenib.Approved, Investigational
Arsenic trioxideDabrafenib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Dabrafenib.Approved
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Dabrafenib.Approved
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Dabrafenib.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Dabrafenib.Approved, Investigational
AtomoxetineThe serum concentration of Atomoxetine can be decreased when it is combined with Dabrafenib.Approved
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Dabrafenib.Approved
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Dabrafenib.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Dabrafenib.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Dabrafenib.Approved
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Dabrafenib.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Dabrafenib.Investigational
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Dabrafenib.Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Dabrafenib.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Dabrafenib.Investigational
BenzatropineThe serum concentration of Benzatropine can be decreased when it is combined with Dabrafenib.Approved
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Dabrafenib.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Dabrafenib.Approved
BeraprostThe serum concentration of Beraprost can be decreased when it is combined with Dabrafenib.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Dabrafenib.Approved, Investigational
BexaroteneThe serum concentration of Bexarotene can be decreased when it is combined with Dabrafenib.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Dabrafenib.Approved
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Dabrafenib.Approved
Bismuth SubcitrateThe serum concentration of Dabrafenib can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Dabrafenib can be decreased when it is combined with Bismuth subnitrate.Experimental
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Dabrafenib.Approved
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Dabrafenib.Approved, Withdrawn
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Dabrafenib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be decreased when it is combined with Dabrafenib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Dabrafenib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Dabrafenib.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Dabrafenib.Approved
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Dabrafenib.Approved
BrivaracetamThe serum concentration of Brivaracetam can be decreased when it is combined with Dabrafenib.Approved, Investigational
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Dabrafenib.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Dabrafenib.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Dabrafenib.Approved
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Dabrafenib.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Dabrafenib.Investigational, Withdrawn
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Dabrafenib.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Dabrafenib.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Dabrafenib.Approved
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Dabrafenib.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Dabrafenib.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Dabrafenib.Approved
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Dabrafenib.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Dabrafenib.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Dabrafenib.Approved
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Dabrafenib.Approved, Nutraceutical
Calcium CarbonateThe serum concentration of Dabrafenib can be decreased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Dabrafenib can be decreased when it is combined with Calcium silicate.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Dabrafenib.Approved
CandesartanThe serum concentration of Candesartan can be decreased when it is combined with Dabrafenib.Experimental
Candesartan cilexetilThe serum concentration of Candesartan cilexetil can be decreased when it is combined with Dabrafenib.Approved
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Dabrafenib.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Dabrafenib.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Dabrafenib.Experimental
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Dabrafenib.Approved
CarisoprodolThe serum concentration of Carisoprodol can be decreased when it is combined with Dabrafenib.Approved
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Dabrafenib.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Dabrafenib.Experimental
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Dabrafenib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Dabrafenib.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
CeritinibThe serum concentration of Dabrafenib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Dabrafenib.Withdrawn
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Dabrafenib.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Dabrafenib.Approved
ChloramphenicolThe serum concentration of Chloramphenicol can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Dabrafenib.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Dabrafenib.Investigational, Withdrawn
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Dabrafenib.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
ChlorpropamideThe serum concentration of Chlorpropamide can be decreased when it is combined with Dabrafenib.Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Dabrafenib.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Dabrafenib.Approved, Nutraceutical
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Dabrafenib.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Dabrafenib.Experimental
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Dabrafenib.Approved
CimetidineThe serum concentration of Dabrafenib can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Dabrafenib.Approved
CinnarizineThe serum concentration of Cinnarizine can be decreased when it is combined with Dabrafenib.Approved, Investigational
CiprofloxacinDabrafenib may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Dabrafenib.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Dabrafenib.Approved
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Dabrafenib.Approved
ClemastineThe metabolism of Dabrafenib can be decreased when combined with Clemastine.Approved
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Dabrafenib.Approved, Illicit
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Dabrafenib.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Dabrafenib.Approved, Investigational
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Dabrafenib.Investigational
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Dabrafenib.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Dabrafenib.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Dabrafenib.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Dabrafenib.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Dabrafenib.Approved, Illicit
ClotrimazoleThe metabolism of Dabrafenib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Dabrafenib.Approved
CobicistatThe metabolism of Dabrafenib can be decreased when combined with Cobicistat.Approved
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Dabrafenib.Approved, Illicit
CodeineThe serum concentration of Codeine can be decreased when it is combined with Dabrafenib.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Dabrafenib.Approved
ConivaptanThe serum concentration of Conivaptan can be decreased when it is combined with Dabrafenib.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Dabrafenib.Approved
CopanlisibThe serum concentration of Copanlisib can be decreased when it is combined with Dabrafenib.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Dabrafenib.Approved
CrisaboroleThe metabolism of Dabrafenib can be decreased when combined with Crisaborole.Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Dabrafenib.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Dabrafenib.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Dabrafenib.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Dabrafenib.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Dabrafenib.Experimental
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Dabrafenib.Approved
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Dabrafenib.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Dabrafenib.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Dabrafenib.Approved
DeferasiroxThe serum concentration of Dabrafenib can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe serum concentration of Deflazacort can be decreased when it is combined with Dabrafenib.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Dabrafenib.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Dabrafenib.Investigational
DesipramineThe serum concentration of Desipramine can be decreased when it is combined with Dabrafenib.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Dabrafenib.Approved
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Dabrafenib.Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Dabrafenib.Approved
DeutetrabenazineThe serum concentration of Deutetrabenazine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Dabrafenib.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe serum concentration of Dexchlorpheniramine maleate can be decreased when it is combined with Dabrafenib.Approved
DexlansoprazoleThe serum concentration of Dabrafenib can be decreased when it is combined with Dexlansoprazole.Approved
DexrabeprazoleThe serum concentration of Dabrafenib can be decreased when it is combined with Dexrabeprazole.Experimental
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Dabrafenib.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Dabrafenib.Approved, Illicit, Investigational, Withdrawn
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Dabrafenib.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be decreased when it is combined with Dabrafenib.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Dabrafenib.Approved, Investigational
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Dabrafenib.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Dabrafenib.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Dabrafenib.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Dabrafenib.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Dabrafenib.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Dabrafenib.Approved
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Dabrafenib.Approved
DiphenhydramineThe serum concentration of Diphenhydramine can be decreased when it is combined with Dabrafenib.Approved
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Dabrafenib.Approved
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Dabrafenib.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Dabrafenib.Approved, Investigational
DoconexentThe serum concentration of Doconexent can be decreased when it is combined with Dabrafenib.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Dabrafenib.Approved
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Dabrafenib.Approved
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Dabrafenib.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Dabrafenib.Approved
DopamineThe serum concentration of Dopamine can be decreased when it is combined with Dabrafenib.Approved
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Dabrafenib.Approved
DoxazosinThe serum concentration of Doxazosin can be decreased when it is combined with Dabrafenib.Approved
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Dabrafenib.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DoxycyclineThe metabolism of Dabrafenib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Dabrafenib.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Dabrafenib.Approved
DroperidolDabrafenib may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Dabrafenib.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Dabrafenib.Approved
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Dabrafenib.Approved, Investigational
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Dabrafenib.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be decreased when it is combined with Dabrafenib.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Dabrafenib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Dabrafenib.Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Dabrafenib.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Dabrafenib.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dabrafenib.Approved
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
EnasidenibThe serum concentration of Enasidenib can be decreased when it is combined with Dabrafenib.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be decreased when it is combined with Dabrafenib.Approved, Investigational
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Dabrafenib.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Dabrafenib.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Dabrafenib.Approved
EpoprostenolThe serum concentration of Epoprostenol can be decreased when it is combined with Dabrafenib.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Dabrafenib.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Dabrafenib.Approved
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Dabrafenib.Approved
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Dabrafenib.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Dabrafenib.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Dabrafenib.Approved, Investigational
EsomeprazoleThe serum concentration of Dabrafenib can be decreased when it is combined with Esomeprazole.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Dabrafenib.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Dabrafenib.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be decreased when it is combined with Dabrafenib.Approved, Investigational
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Dabrafenib.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Dabrafenib.Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Dabrafenib.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Dabrafenib.Approved
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Dabrafenib.Approved
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Dabrafenib.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Dabrafenib.Approved
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Dabrafenib.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Dabrafenib.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Dabrafenib.Approved
EtizolamThe serum concentration of Etizolam can be decreased when it is combined with Dabrafenib.Approved
EtodolacThe serum concentration of Etodolac can be decreased when it is combined with Dabrafenib.Approved, Investigational, Vet Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Dabrafenib.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Dabrafenib.Approved
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Dabrafenib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Dabrafenib.Approved
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Dabrafenib.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Dabrafenib.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Dabrafenib.Approved, Investigational
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Dabrafenib.Approved
FamotidineThe serum concentration of Famotidine can be decreased when it is combined with Dabrafenib.Approved
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Dabrafenib.Approved
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Dabrafenib.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Dabrafenib.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Dabrafenib.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Dabrafenib.Approved
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Dabrafenib.Approved
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Dabrafenib.Approved, Investigational
FlecainideDabrafenib may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Dabrafenib.Approved
FluconazoleThe metabolism of Dabrafenib can be decreased when combined with Fluconazole.Approved
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Dabrafenib.Approved
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Dabrafenib.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Dabrafenib.Approved, Illicit
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Dabrafenib.Approved
FluorouracilThe serum concentration of Fluorouracil can be decreased when it is combined with Dabrafenib.Approved
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
FlupentixolDabrafenib may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Dabrafenib.Approved, Illicit
FlurbiprofenThe serum concentration of Flurbiprofen can be decreased when it is combined with Dabrafenib.Approved, Investigational
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Dabrafenib.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Dabrafenib.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be decreased when it is combined with Dabrafenib.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Dabrafenib.Approved
FluvoxamineThe metabolism of Dabrafenib can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe serum concentration of Formoterol can be decreased when it is combined with Dabrafenib.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Dabrafenib.Approved
FosaprepitantThe serum concentration of Dabrafenib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be decreased when it is combined with Dabrafenib.Approved
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Dabrafenib.Approved, Investigational
Fusidic AcidThe serum concentration of Dabrafenib can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidDabrafenib may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Dabrafenib.Approved
GavestinelThe serum concentration of Gavestinel can be decreased when it is combined with Dabrafenib.Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Dabrafenib.Approved, Investigational
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Dabrafenib.Approved
GemifloxacinDabrafenib may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Dabrafenib.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Dabrafenib.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Dabrafenib.Investigational, Withdrawn
GliclazideThe serum concentration of Gliclazide can be decreased when it is combined with Dabrafenib.Approved
GlimepirideThe serum concentration of Glimepiride can be decreased when it is combined with Dabrafenib.Approved
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Dabrafenib.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Dabrafenib.Approved, Investigational
GlucosamineThe serum concentration of Glucosamine can be decreased when it is combined with Dabrafenib.Approved
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Dabrafenib.Approved
GoserelinDabrafenib may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Dabrafenib.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Dabrafenib.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Dabrafenib.Investigational, Withdrawn
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Dabrafenib.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Dabrafenib.Investigational
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Dabrafenib.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Dabrafenib.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Dabrafenib.Withdrawn
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Dabrafenib.Approved
HistamineThe serum concentration of Histamine can be decreased when it is combined with Dabrafenib.Approved, Investigational
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Dabrafenib.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Dabrafenib.Approved, Illicit
HydrotalciteThe serum concentration of Dabrafenib can be decreased when it is combined with Hydrotalcite.Experimental, Investigational
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Dabrafenib.Approved
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Dabrafenib.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Dabrafenib.Approved
IbutilideDabrafenib may increase the QTc-prolonging activities of Ibutilide.Approved
IcotinibThe serum concentration of Icotinib can be decreased when it is combined with Dabrafenib.Approved, Investigational
IdarubicinThe serum concentration of Idarubicin can be decreased when it is combined with Dabrafenib.Approved
IdelalisibThe serum concentration of Dabrafenib can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Ifosfamide can be decreased when it is combined with Dabrafenib.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Dabrafenib.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Dabrafenib.Approved
ImidafenacinThe serum concentration of Imidafenacin can be decreased when it is combined with Dabrafenib.Approved, Investigational
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Dabrafenib.Approved
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Dabrafenib.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Dabrafenib.Approved
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Dabrafenib.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Dabrafenib.Approved
indisulamThe serum concentration of indisulam can be decreased when it is combined with Dabrafenib.Investigational
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Dabrafenib.Approved, Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Dabrafenib.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Dabrafenib.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Dabrafenib.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Dabrafenib.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Dabrafenib.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dabrafenib.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Dabrafenib.Approved
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Dabrafenib.Approved
IrbesartanThe serum concentration of Irbesartan can be decreased when it is combined with Dabrafenib.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Dabrafenib.Approved, Investigational
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Dabrafenib.Approved, Investigational
IsofluraneThe serum concentration of Isoflurane can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Dabrafenib.Approved
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Dabrafenib.Approved
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Dabrafenib.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Dabrafenib.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Dabrafenib.Approved
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Dabrafenib.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Dabrafenib.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Dabrafenib.Approved
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Dabrafenib.Approved
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Dabrafenib.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Dabrafenib.Approved, Investigational
KetoprofenThe serum concentration of Ketoprofen can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Dabrafenib.Experimental
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Dabrafenib.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Dabrafenib.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Dabrafenib.Investigational
LeflunomideThe serum concentration of Leflunomide can be decreased when it is combined with Dabrafenib.Approved, Investigational
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Dabrafenib.Approved
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Dabrafenib.Approved, Investigational
LesinuradThe serum concentration of Lesinurad can be decreased when it is combined with Dabrafenib.Approved
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Dabrafenib.Approved, Investigational
LeuprolideDabrafenib may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Dabrafenib.Approved, Investigational
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Dabrafenib.Approved
LevofloxacinDabrafenib may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Dabrafenib.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Dabrafenib.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Dabrafenib.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Dabrafenib.Approved
LicofeloneThe serum concentration of Licofelone can be decreased when it is combined with Dabrafenib.Investigational
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Dabrafenib.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Dabrafenib.Approved
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Dabrafenib.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Dabrafenib.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Dabrafenib.Approved
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Dabrafenib.Approved
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Dabrafenib.Approved
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Dabrafenib.Approved
LornoxicamThe serum concentration of Lornoxicam can be decreased when it is combined with Dabrafenib.Approved, Investigational
LosartanThe serum concentration of Losartan can be decreased when it is combined with Dabrafenib.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Dabrafenib.Approved, Investigational
LuliconazoleThe serum concentration of Dabrafenib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Dabrafenib can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Dabrafenib.Approved
LumiracoxibThe serum concentration of Lumiracoxib can be decreased when it is combined with Dabrafenib.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Dabrafenib.Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Dabrafenib.Investigational
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Dabrafenib.Approved
MagaldrateThe serum concentration of Dabrafenib can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium Trisilicate.Approved
MalathionThe serum concentration of Malathion can be decreased when it is combined with Dabrafenib.Approved, Investigational
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Dabrafenib.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Dabrafenib.Approved, Investigational
Mefenamic acidThe serum concentration of Mefenamic acid can be decreased when it is combined with Dabrafenib.Approved
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Dabrafenib.Approved
MelatoninThe serum concentration of Melatonin can be decreased when it is combined with Dabrafenib.Approved, Nutraceutical, Vet Approved
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
MephenytoinThe serum concentration of Mephenytoin can be decreased when it is combined with Dabrafenib.Investigational, Withdrawn
MeprobamateThe serum concentration of Meprobamate can be decreased when it is combined with Dabrafenib.Approved, Illicit
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Dabrafenib.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Dabrafenib.Approved
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Dabrafenib.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Dabrafenib.Experimental
MethanthelineThe serum concentration of Dabrafenib can be decreased when it is combined with Methantheline.Approved, Investigational
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Dabrafenib.Illicit, Withdrawn
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Dabrafenib.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Dabrafenib.Approved, Investigational, Vet Approved
MethsuximideThe serum concentration of Methsuximide can be decreased when it is combined with Dabrafenib.Approved
MethylphenobarbitalThe serum concentration of Methylphenobarbital can be decreased when it is combined with Dabrafenib.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Dabrafenib.Approved
MetiamideThe serum concentration of Dabrafenib can be decreased when it is combined with Metiamide.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Dabrafenib.Experimental
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Dabrafenib.Approved, Investigational
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Dabrafenib.Approved
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Dabrafenib.Approved
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Dabrafenib.Approved, Investigational
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Dabrafenib.Investigational, Withdrawn
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Dabrafenib.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Dabrafenib.Approved, Illicit
MidostaurinThe serum concentration of Midostaurin can be decreased when it is combined with Dabrafenib.Approved
MifepristoneThe serum concentration of Dabrafenib can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Dabrafenib.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Dabrafenib.Approved
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Dabrafenib.Approved
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Dabrafenib.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Dabrafenib.Approved, Investigational
MitotaneThe serum concentration of Dabrafenib can be decreased when it is combined with Mitotane.Approved
MoclobemideThe serum concentration of Moclobemide can be decreased when it is combined with Dabrafenib.Approved
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Dabrafenib.Approved, Investigational
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Dabrafenib.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Dabrafenib.Approved, Investigational
MoxifloxacinDabrafenib may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
muraglitazarThe serum concentration of muraglitazar can be decreased when it is combined with Dabrafenib.Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Dabrafenib.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Dabrafenib.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
NaproxenThe serum concentration of Naproxen can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Dabrafenib.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Dabrafenib.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Dabrafenib.Approved
NeratinibThe serum concentration of Neratinib can be decreased when it is combined with Dabrafenib.Approved, Investigational
NetupitantThe serum concentration of Netupitant can be decreased when it is combined with Dabrafenib.Approved
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Dabrafenib.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Dabrafenib.Approved
NiclosamideThe serum concentration of Niclosamide can be decreased when it is combined with Dabrafenib.Approved, Investigational, Vet Approved
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Dabrafenib.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Dabrafenib.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Dabrafenib.Approved, Investigational
NilutamideThe serum concentration of Nilutamide can be decreased when it is combined with Dabrafenib.Approved
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Dabrafenib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Dabrafenib.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Dabrafenib.Approved
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Dabrafenib.Approved
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Dabrafenib.Approved, Investigational
NizatidineThe serum concentration of Dabrafenib can be decreased when it is combined with Nizatidine.Approved
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Dabrafenib.Approved
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Dabrafenib.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Dabrafenib.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Dabrafenib.Approved
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Dabrafenib.Approved
OdanacatibThe serum concentration of Odanacatib can be decreased when it is combined with Dabrafenib.Investigational
OfloxacinDabrafenib may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Dabrafenib can be decreased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Dabrafenib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Dabrafenib.Experimental, Investigational
OlodaterolThe serum concentration of Olodaterol can be decreased when it is combined with Dabrafenib.Approved
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Dabrafenib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Dabrafenib.Approved
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Dabrafenib.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Dabrafenib.Approved
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Dabrafenib.Approved
OsimertinibThe serum concentration of Dabrafenib can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Dabrafenib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Dabrafenib.Approved
OxaprozinThe serum concentration of Oxaprozin can be decreased when it is combined with Dabrafenib.Approved
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Dabrafenib.Approved
OxiconazoleThe serum concentration of Oxiconazole can be decreased when it is combined with Dabrafenib.Approved
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Dabrafenib.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Dabrafenib.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Dabrafenib.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Dabrafenib.Approved
PaliperidoneDabrafenib may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Dabrafenib.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Dabrafenib.Approved, Investigational
PantoprazoleThe serum concentration of Dabrafenib can be decreased when it is combined with Pantoprazole.Approved
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Dabrafenib.Approved
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Dabrafenib.Approved
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Dabrafenib.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Dabrafenib.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Dabrafenib.Approved
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Dabrafenib.Approved
PentobarbitalThe serum concentration of Pentobarbital can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Dabrafenib.Approved
PerflutrenDabrafenib may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Dabrafenib.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Dabrafenib.Approved, Investigational
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Dabrafenib.Approved, Investigational
PerospironeThe serum concentration of Perospirone can be decreased when it is combined with Dabrafenib.Approved
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Dabrafenib.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Dabrafenib.Experimental
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Dabrafenib.Approved
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Dabrafenib.Withdrawn
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Dabrafenib.Approved, Investigational, Withdrawn
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Dabrafenib.Approved
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Dabrafenib.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Dabrafenib.Approved, Investigational
PhenylbutazoneThe serum concentration of Phenylbutazone can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Dabrafenib.Approved
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Dabrafenib.Approved, Investigational
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Dabrafenib.Approved
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Dabrafenib.Withdrawn
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Dabrafenib.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Dabrafenib.Approved, Investigational
PiroxicamThe serum concentration of Piroxicam can be decreased when it is combined with Dabrafenib.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Dabrafenib.Approved
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Dabrafenib.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Dabrafenib.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Dabrafenib.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Dabrafenib.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Dabrafenib.Approved, Investigational
PrasteroneThe serum concentration of Prasterone can be decreased when it is combined with Dabrafenib.Approved, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Dabrafenib.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Dabrafenib.Approved
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Dabrafenib.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Dabrafenib.Approved
PrimidoneThe serum concentration of Primidone can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
ProcainamideDabrafenib may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Dabrafenib.Approved
PromazineThe serum concentration of Promazine can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be decreased when it is combined with Dabrafenib.Approved
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Dabrafenib.Approved
PropofolThe serum concentration of Propofol can be decreased when it is combined with Dabrafenib.Approved, Investigational, Vet Approved
Propoxyphene napsylateThe serum concentration of Propoxyphene napsylate can be decreased when it is combined with Dabrafenib.Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Dabrafenib.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Dabrafenib.Experimental
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Dabrafenib.Approved
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Dabrafenib.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Dabrafenib.Approved
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Dabrafenib.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Dabrafenib.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Dabrafenib.Approved
RabeprazoleThe serum concentration of Dabrafenib can be decreased when it is combined with Rabeprazole.Approved, Investigational
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Dabrafenib.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Dabrafenib.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Dabrafenib.Approved
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Dabrafenib.Approved, Investigational
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Dabrafenib.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Dabrafenib.Approved
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Dabrafenib.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Dabrafenib.Approved
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Dabrafenib.Approved
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Dabrafenib.Approved
RifapentineThe metabolism of Dabrafenib can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Dabrafenib.Approved
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Dabrafenib.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Dabrafenib.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Dabrafenib.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Dabrafenib.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Dabrafenib.Approved
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Dabrafenib.Investigational, Withdrawn
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Dabrafenib.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Dabrafenib.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Dabrafenib.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Dabrafenib.Approved
RosiglitazoneThe serum concentration of Rosiglitazone can be decreased when it is combined with Dabrafenib.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Dabrafenib.Approved
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Dabrafenib.Approved
Roxatidine acetateThe serum concentration of Dabrafenib can be decreased when it is combined with Roxatidine acetate.Approved, Investigational
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Dabrafenib.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Rucaparib can be decreased when it is combined with Dabrafenib.Approved, Investigational
RupatadineThe serum concentration of Rupatadine can be decreased when it is combined with Dabrafenib.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Dabrafenib.Approved
SafinamideThe serum concentration of Safinamide can be decreased when it is combined with Dabrafenib.Approved
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Dabrafenib.Approved
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Dabrafenib.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Dabrafenib.Approved
SecobarbitalThe metabolism of Dabrafenib can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Dabrafenib.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Dabrafenib.Approved
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Dabrafenib.Approved
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Dabrafenib.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Dabrafenib.Approved
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Dabrafenib.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Dabrafenib.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Dabrafenib.Approved
SiltuximabThe serum concentration of Dabrafenib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Dabrafenib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Dabrafenib.Approved
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Dabrafenib.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Dabrafenib.Approved, Investigational
SitaxentanThe serum concentration of Sitaxentan can be decreased when it is combined with Dabrafenib.Approved, Investigational, Withdrawn
Sodium bicarbonateThe serum concentration of Dabrafenib can be decreased when it is combined with Sodium bicarbonate.Approved
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Dabrafenib.Approved
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Dabrafenib.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Dabrafenib.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Dabrafenib.Investigational
SotalolDabrafenib may increase the QTc-prolonging activities of Sotalol.Approved
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Dabrafenib.Approved
St. John's WortThe serum concentration of Dabrafenib can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Dabrafenib can be increased when it is combined with Stiripentol.Approved
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Dabrafenib.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Dabrafenib.Approved
SulfamoxoleThe serum concentration of Sulfamoxole can be decreased when it is combined with Dabrafenib.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Dabrafenib.Approved
SulfisoxazoleThe serum concentration of Sulfisoxazole can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Dabrafenib.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Dabrafenib.Approved, Investigational
SuprofenThe serum concentration of Suprofen can be decreased when it is combined with Dabrafenib.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Dabrafenib.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Dabrafenib.Approved
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Dabrafenib.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Dabrafenib.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Dabrafenib.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Dabrafenib.Approved, Investigational
TapentadolThe serum concentration of Tapentadol can be decreased when it is combined with Dabrafenib.Approved
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Dabrafenib.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Dabrafenib.Experimental
TazaroteneThe serum concentration of Tazarotene can be decreased when it is combined with Dabrafenib.Approved, Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Dabrafenib.Approved, Withdrawn
TelavancinDabrafenib may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Dabrafenib.Approved
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Dabrafenib.Approved
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Dabrafenib.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Dabrafenib.Approved
TenoxicamThe serum concentration of Tenoxicam can be decreased when it is combined with Dabrafenib.Approved
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Dabrafenib.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Dabrafenib.Withdrawn
TeriflunomideThe serum concentration of Dabrafenib can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Dabrafenib.Investigational
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Dabrafenib.Approved, Investigational
TetrabenazineDabrafenib may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
ThalidomideThe serum concentration of Thalidomide can be decreased when it is combined with Dabrafenib.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Dabrafenib.Approved
ThiamylalThe serum concentration of Thiamylal can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be decreased when it is combined with Dabrafenib.Approved, Withdrawn
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Dabrafenib.Approved
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Dabrafenib.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Dabrafenib.Approved
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Dabrafenib.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Dabrafenib.Approved
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Dabrafenib.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Dabrafenib.Approved
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Dabrafenib.Approved, Investigational
TocilizumabThe serum concentration of Dabrafenib can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Dabrafenib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Dabrafenib.Approved
TolbutamideThe serum concentration of Tolbutamide can be decreased when it is combined with Dabrafenib.Approved
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Dabrafenib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Dabrafenib.Approved
TopiroxostatThe metabolism of Dabrafenib can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dabrafenib.Approved, Investigational
TorasemideThe serum concentration of Torasemide can be decreased when it is combined with Dabrafenib.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Dabrafenib.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Dabrafenib.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Dabrafenib.Approved, Investigational
TrametinibThe risk or severity of adverse effects can be increased when Trametinib is combined with Dabrafenib.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Dabrafenib.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Dabrafenib.Approved
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Dabrafenib.Approved, Investigational
TreprostinilThe serum concentration of Treprostinil can be decreased when it is combined with Dabrafenib.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Dabrafenib.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Dabrafenib.Approved
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Dabrafenib.Approved
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Dabrafenib.Approved
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Dabrafenib.Investigational, Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Dabrafenib.Approved
TromethamineThe serum concentration of Dabrafenib can be decreased when it is combined with Tromethamine.Approved
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Dabrafenib.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Dabrafenib.Approved
ValbenazineThe serum concentration of Valbenazine can be decreased when it is combined with Dabrafenib.Approved, Investigational
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Dabrafenib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Dabrafenib.Approved, Investigational
ValsartanThe serum concentration of Valsartan can be decreased when it is combined with Dabrafenib.Approved, Investigational
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Dabrafenib.Approved
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Dabrafenib.Investigational
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Dabrafenib.Approved
VelpatasvirThe serum concentration of Velpatasvir can be decreased when it is combined with Dabrafenib.Approved
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Dabrafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Dabrafenib.Approved
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Dabrafenib.Approved
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Dabrafenib.Approved
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Dabrafenib.Investigational
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Dabrafenib.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Dabrafenib.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Dabrafenib.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Dabrafenib.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Dabrafenib.Approved, Investigational
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Dabrafenib.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Dabrafenib.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Dabrafenib.Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Dabrafenib.Approved, Investigational
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Dabrafenib.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Dabrafenib.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be decreased when it is combined with Dabrafenib.Approved
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Dabrafenib.Approved
XimelagatranThe serum concentration of Ximelagatran can be decreased when it is combined with Dabrafenib.Approved, Investigational, Withdrawn
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Dabrafenib.Approved, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Dabrafenib.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Dabrafenib.Approved, Investigational
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Dabrafenib.Approved, Illicit, Investigational
ZaltoprofenThe serum concentration of Zaltoprofen can be decreased when it is combined with Dabrafenib.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Dabrafenib.Approved
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Dabrafenib.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Dabrafenib.Approved
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Dabrafenib.Approved
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Dabrafenib.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Dabrafenib.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Dabrafenib.Approved
ZuclopenthixolDabrafenib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • When taken with a fatty meal, Cmax and AUC decreased. Tmax is also prolonged compared to the fasted condition.

References

General References
  1. Gibney GT, Zager JS: Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):893-9. doi: 10.1517/17425255.2013.794220. Epub 2013 Apr 29. [PubMed:23621583]
External Links
KEGG Drug
D10064
PubChem Compound
44462760
PubChem Substance
175427150
ChemSpider
25948204
BindingDB
50428286
ChEBI
75045
ChEMBL
CHEMBL2028663
HET
P06
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Dabrafenib
ATC Codes
L01XE23 — Dabrafenib
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
4xv2 / 5csw / 5hie
FDA label
Download (418 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAdult Solid Neoplasm / BRAF Gene Mutation / Hepatic Complications / Renal Failure / Solid Neoplasms1
1Active Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancers7
1CompletedTreatmentTumors, Solid1
1Not Yet RecruitingTreatmentBRAF Gene Mutation / Melanoma1
1RecruitingBasic ScienceHepatic Impairment1
1RecruitingBasic ScienceImpaired Renal Function1
1RecruitingTreatmentBRAF V600E Mutation Present / BRAF V600K Mutation Present / Metastatic Malignant Neoplasm in the Thyroid Gland / Metastatic Thyroid Gland Carcinoma / Recurrent Thyroid Gland Carcinoma / Unresectable Thyroid Gland Carcinoma1
1RecruitingTreatmentBRAF V600E Mutation Present / BRAF V600K Mutation Present / Metastatic Malignant Solid Neoplasm / Metastatic Melanoma / Metastatic Solid Neoplasm / Recurrent Malignant Solid Neoplasm / Recurrent Melanoma / Recurrent Solid Neoplasm / Solid Neoplasms / Stage III Cutaneous Melanoma AJCC v7 / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIA Skin Melanoma / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIB Skin Melanoma / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IIIC Skin Melanoma / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Skin Melanoma / Stages III Skin Melanoma / Unresectable Solid Neoplasm1
1RecruitingTreatmentBRAF V600E Mutation Present / BRAF V600K Mutation Present / Metastatic Melanoma / Stage III Cutaneous Melanoma AJCC v7 / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIA Skin Melanoma / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIB Skin Melanoma / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IIIC Skin Melanoma / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Skin Melanoma / Stages III Skin Melanoma1
1RecruitingTreatmentCancers2
1RecruitingTreatmentMelanoma2
1RecruitingTreatmentMultiple Myeloma (MM)1
1RecruitingTreatmentNeoplasms, Brain1
1TerminatedTreatmentStage III or IV Melanoma1
1WithdrawnTreatmentMelanoma1
1WithdrawnTreatmentMetastatic Melanoma1
1, 2Active Not RecruitingTreatmentMelanoma1
1, 2RecruitingTreatmentAdvanced Malignancy / Advanced Solid Tumors / Cancers / Melanoma / Oncology / Oncology Patients / Tumors1
1, 2RecruitingTreatmentMelanoma3
1, 2RecruitingTreatmentMelanoma / Tumors, Solid1
1, 2RecruitingTreatmentMetastatic Melanoma1
1, 2RecruitingTreatmentMetastatic Melanoma / Recurrent Melanoma / Solid Neoplasms / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIA Skin Melanoma / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIB Skin Melanoma / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IIIC Skin Melanoma / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Skin Melanoma1
1, 2SuspendedTreatmentAdult Solid Neoplasm / Recurrent Colon Carcinoma / Recurrent Melanoma / Recurrent Ovarian Carcinoma / Stage IIIC Colon Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
2Active Not RecruitingTreatmentBRAF Mutant Melanoma / Stage III Melanoma / Stage IV Melanoma / Unresectable Melanoma1
2Active Not RecruitingTreatmentCancers3
2Active Not RecruitingTreatmentFollicular Thyroid Cancer / Insular Thyroid Cancer / Recurrent Thyroid Cancer / Thyroid Papillary Carcinoma1
2Active Not RecruitingTreatmentMalignant Melanoma1
2Active Not RecruitingTreatmentMelanoma2
2Active Not RecruitingTreatmentMelanoma and Brain Metastases1
2Active Not RecruitingTreatmentMetastatic Cancers1
2Active Not RecruitingTreatmentMetastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation1
2Active Not RecruitingTreatmentTumors, Solid1
2CompletedDiagnosticMelanoma1
2CompletedTreatmentBRAFV600E Melanoma Patients1
2CompletedTreatmentMelanoma2
2CompletedTreatmentMelanoma and Brain Metastases2
2Not Yet RecruitingTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Ependymoma / Anaplastic Ganglioglioma / Anaplastic Hemangiopericytoma / Anaplastic Oligoastrocytoma / Anaplastic Oligodendroglioma (AO) / Choroid Plexus Carcinoma / Giant Cell Glioblastoma / Glioblastomas / Gliosarcoma / Malignant Meningloma / Medulloblastomas / MPNST / Perineurioma / Pineal Parenchymal Tumor / Pinealoblastoma / PNET / Rhabdoid Tumors1
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Not Yet RecruitingTreatmentMelanoma / Metastatic Brain Tumors1
2Not Yet RecruitingTreatmentMetastatic Melanoma1
2RecruitingTreatmentAdvanced Malignant Neoplasm / Advanced Malignant Solid Neoplasm / Bladder Carcinoma / Carcinoma, Breast / Carcinoma, Colorectal / Carcinoma, Pancreatic / Cervical Carcinoma / Colon Carcinoma / Endometrial Carcinoma / Gastric Carcinoma / Gliomas / Head and Neck Carcinoma / Liver and Intrahepatic Bile Duct Carcinoma / Lung, Carcinoma / Malignant Lymphomas / Malignant Uterine Neoplasm / Melanoma / Oesophageal Carcinoma / Ovarian Carcinoma / Plasma Cell Myeloma / Prostate Cancer / Rectal Carcinoma / Recurrent Bladder Carcinoma / Recurrent Breast Carcinoma / Recurrent Cervical Carcinoma / Recurrent Colon Carcinoma / Recurrent Colorectal Carcinoma / Recurrent Esophageal Carcinoma / Recurrent Gastric Carcinoma / Recurrent Gliomas / Recurrent Head and Neck Carcinoma / Recurrent Liver Carcinoma / Recurrent Lung Carcinoma / Recurrent Lymphoma / Recurrent Malignant Solid Neoplasm / Recurrent Melanoma / Recurrent Ovarian Carcinoma / Recurrent Pancreatic Carcinoma / Recurrent Plasma Cell Myeloma / Recurrent Prostate Carcinoma / Recurrent Rectal Carcinoma / Recurrent Skin Carcinoma / Recurrent Solid Neoplasm / Recurrent Thyroid Gland Carcinoma / Recurrent Uterine Corpus Carcinoma / Refractory Lymphomas / Refractory Malignant Neoplasm / Refractory Malignant Solid Neoplasm / Refractory Plasma Cell Myeloma / Renal Carcinoma / Skin Carcinoma / Solid Neoplasms / Thyroid Gland Carcinoma / Uterine Corpus Cancer1
2RecruitingTreatmentAmeloblastoma / BRAF Gene Mutation1
2RecruitingTreatmentBRAF V600E Mutation Present / BRAF V600K Mutation Present / Recurrent Melanoma / Stage III Cutaneous Melanoma AJCC v7 / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIA Skin Melanoma / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIB Skin Melanoma / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IIIC Skin Melanoma / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Skin Melanoma / Stages III Skin Melanoma1
2RecruitingTreatmentCancers2
2RecruitingTreatmentCancers / Neoplasia / Neoplasms / Tumors1
2RecruitingTreatmentMalignant Melanoma1
2RecruitingTreatmentMalignant Melanoma Stage IV / Melanoma / Metastatic Melanoma1
2RecruitingTreatmentMelanoma2
2RecruitingTreatmentMetastatic Melanoma1
2RecruitingTreatmentRare Tumor / Refractory Tumors1
2SuspendedTreatmentBRAF V600E Mutation1
2TerminatedOtherRecurrent Melanoma / Stage IIB Melanoma (Locally Advanced) / Stage IIC Melanoma (Locally Advanced) / Stage IIIA Melanoma / Stage IIIB Melanoma / Stage IIIc Melanoma / Stage IV Melanoma (Limited, Resectable)1
2TerminatedTreatmentMetastatic Melanoma (Carrying BRAF V600 Mutation)1
3Active Not RecruitingTreatmentMelanoma3
3CompletedTreatmentCancers1
3RecruitingTreatmentBRAF NP_004324.2:p.V600X / BRAF V600E Mutation Present / BRAF V600K Mutation Present / Metastatic Melanoma / Recurrent Melanoma / Stage III Cutaneous Melanoma AJCC v7 / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIA Skin Melanoma / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIB Skin Melanoma / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IIIC Skin Melanoma / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Skin Melanoma / Stages III Skin Melanoma1
3RecruitingTreatmentMelanoma2
4Not Yet RecruitingTreatmentHigh Grade Glioma (HGG) / Lung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Rare Cancers / Tumors, Solid1
Not AvailableCompletedTreatmentPapillary Thyroid Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral50 mg
CapsuleOral50 mg/1
CapsuleOral75 mg/1
CapsuleOral75 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7994185No2010-01-202030-01-20Us
US8415345No2010-01-202030-01-20Us
US9233956No2009-05-042029-05-04Us
US8703781No2010-10-152030-10-15Us
US8835443No2005-09-132025-09-13Us
US8952018No2010-10-152030-10-15Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00327 mg/mLALOGPS
logP5.44ALOGPS
logP5.46ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)7.16ChemAxon
pKa (Strongest Basic)2.91ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area110.86 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity127.51 m3·mol-1ChemAxon
Polarizability49.71 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9944
Blood Brain Barrier+0.7232
Caco-2 permeable+0.5069
P-glycoprotein substrateNon-substrate0.7965
P-glycoprotein inhibitor INon-inhibitor0.6468
P-glycoprotein inhibitor IINon-inhibitor0.7039
Renal organic cation transporterNon-inhibitor0.8694
CYP450 2C9 substrateNon-substrate0.8233
CYP450 2D6 substrateNon-substrate0.7346
CYP450 3A4 substrateNon-substrate0.5834
CYP450 1A2 substrateInhibitor0.5219
CYP450 2C9 inhibitorInhibitor0.5
CYP450 2D6 inhibitorNon-inhibitor0.8459
CYP450 2C19 inhibitorNon-inhibitor0.5
CYP450 3A4 inhibitorInhibitor0.7531
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8612
Ames testNon AMES toxic0.7078
CarcinogenicityNon-carcinogens0.8093
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4329 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9848
hERG inhibition (predictor II)Non-inhibitor0.7704
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as sulfanilides. These are organic aromatic compounds containing a sulfanilide moiety, with the general structure RS(=O)(=O)NC1=CC=CC=C1.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Sulfanilides
Direct Parent
Sulfanilides
Alternative Parents
Benzenesulfonamides / Benzenesulfonyl compounds / 2,4,5-trisubstituted thiazoles / Fluorobenzenes / Aminopyrimidines and derivatives / Organosulfonamides / Aryl fluorides / Heteroaromatic compounds / Aminosulfonyl compounds / Azacyclic compounds
show 5 more
Substituents
Benzenesulfonamide / Sulfanilide / Benzenesulfonyl group / 2,4,5-trisubstituted 1,3-thiazole / Aminopyrimidine / Fluorobenzene / Halobenzene / Aryl fluoride / Aryl halide / Pyrimidine
show 22 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, aminopyrimidine, sulfonamide, 1,3-thiazole (CHEBI:75045)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein serine/threonine kinase activity
Specific Function
Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, a...
Gene Name
BRAF
Uniprot ID
P15056
Uniprot Name
Serine/threonine-protein kinase B-raf
Molecular Weight
84436.135 Da
References
  1. Gibney GT, Zager JS: Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):893-9. doi: 10.1517/17425255.2013.794220. Epub 2013 Apr 29. [PubMed:23621583]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein serine/threonine kinase activity
Specific Function
Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determin...
Gene Name
RAF1
Uniprot ID
P04049
Uniprot Name
RAF proto-oncogene serine/threonine-protein kinase
Molecular Weight
73051.025 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein serine/threonine kinase activity
Specific Function
Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, gluconeogenesis and lipogenesis regulation, muscle growth and differentiation and tumor suppression. Pho...
Gene Name
SIK1
Uniprot ID
P57059
Uniprot Name
Serine/threonine-protein kinase SIK1
Molecular Weight
84901.25 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein serine/threonine kinase activity
Specific Function
Protein kinase which plays an important role in the G2/M checkpoint response to DNA damage. Controls degradation of CDC25A by directly phosphorylating it on residues whose phosphorylation is requir...
Gene Name
NEK11
Uniprot ID
Q8NG66
Uniprot Name
Serine/threonine-protein kinase Nek11
Molecular Weight
74191.62 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Serine/threonine-protein kinase that plays an essential role in the regulation of actin filament dynamics. Acts downstream of several Rho family GTPase signal transduction pathways. Activated by up...
Gene Name
LIMK1
Uniprot ID
P53667
Uniprot Name
LIM domain kinase 1
Molecular Weight
72584.4 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF: Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64. doi: 10.1124/jpet.112.201475. Epub 2012 Dec 17. [PubMed:23249624]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF: Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64. doi: 10.1124/jpet.112.201475. Epub 2012 Dec 17. [PubMed:23249624]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da

Drug created on June 24, 2013 15:54 / Updated on November 19, 2017 20:33